NCT06344975View on ClinicalTrials.gov

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy Adults

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

May 31, 2025

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

STR-V003/Placebo

IM

Sponsors
All Listed Sponsors
lead

Starna Therapeutics

INDUSTRY

NCT06344975 - A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy Adults | Biotech Hunter | Biotech Hunter